Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DMAC 
DiaMedica Therapeutics Inc (DMAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: DMAC (4-star) is a STRONG-BUY. BUY since 40 days. Simulated Profits (51.52%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.33
1 Year Target Price $12.33
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 98.53% | Avg. Invested days 42 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 366.47M USD | Price to earnings Ratio - | 1Y Target Price 12.33 |
Price to earnings Ratio - | 1Y Target Price 12.33 | ||
Volume (30-day avg) 4 | Beta 1.4 | 52 Weeks Range 3.19 - 7.49 | Updated Date 09/15/2025 |
52 Weeks Range 3.19 - 7.49 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.54% | Return on Equity (TTM) -73.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 336728393 | Price to Sales(TTM) - |
Enterprise Value 336728393 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.96 | Shares Outstanding 51688900 | Shares Floating 27067416 |
Shares Outstanding 51688900 | Shares Floating 27067416 | ||
Percent Insiders 33.51 | Percent Institutions 37.65 |
Upturn AI SWOT
DiaMedica Therapeutics Inc
Company Overview
History and Background
DiaMedica Therapeutics Inc. was founded in 2004. The company focuses on developing treatments for neurological and kidney diseases, particularly those related to vascular and inflammatory processes. It has primarily focused on developing DM199, a recombinant form of human tissue kallikrein-1 (KLK1).
Core Business Areas
- Pharmaceutical Development: DiaMedica focuses on the discovery, development, and commercialization of novel therapeutics to treat unmet medical needs in neurological and kidney diseases.
- DM199 Development: The core of their business is the development and clinical testing of DM199 for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD).
Leadership and Structure
The company has a typical biotech structure, with a CEO (Rick Pauls) and a management team overseeing clinical development, regulatory affairs, and finance. The board of directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- DM199 for Acute Ischemic Stroke (AIS): DM199 is a recombinant human tissue kallikrein-1 (KLK1) being developed for the treatment of AIS. It aims to improve outcomes by promoting vasodilation and reducing inflammation. Since it is still in trials, there is no market share or revenue to list at this stage. Competitors include companies working on other thrombolytic agents (e.g., alteplase), neuroprotective drugs, and devices for stroke intervention.
- DM199 for Chronic Kidney Disease (CKD): DM199 is also in development for CKD, targeting patients with specific genetic deficiencies of KLK1. It is hoped to improve kidney function and prevent further damage. Since it is still in trials, there is no market share or revenue to list at this stage. Competitors include companies developing ACE inhibitors, ARBs, SGLT2 inhibitors, and other therapies for CKD.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk and high reward. Companies developing novel therapeutics face substantial regulatory hurdles, clinical trial expenses, and competition. The neurological and nephrology markets are substantial, with significant unmet needs.
Positioning
DiaMedica is a clinical-stage biotech company focused on a specific target (KLK1) with potential applications in multiple therapeutic areas. Their competitive advantage lies in the novelty of their approach and the potential for DM199 to address unmet needs in stroke and kidney disease. A substantial risk factor involves successfully reaching phase 3 and beyond.
Total Addressable Market (TAM)
The TAM for stroke and CKD therapies is estimated to be in the billions of dollars globally. DiaMedica's positioning within this TAM depends on the clinical success of DM199 and its ability to differentiate itself from existing treatments. Success would position them to claim a considerable market share, failure means zero market share.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (KLK1)
- Potential for multiple indications (stroke, CKD)
- Orphan drug designation for certain indications
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on a single drug candidate (DM199)
- High clinical trial risk
- Dependence on successful fundraising
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion to new indications
- Grant funding and government support
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- NVS
- LLY
- BMY
- GILD
Competitive Landscape
DiaMedica faces intense competition from established pharmaceutical companies with greater resources. Its competitive advantage relies on the novelty of its therapeutic approach and the potential for DM199 to address unmet needs. It's disadvantages are the clinical stage, funding and other pharmaceutical companies that are working on similar solutions.
Growth Trajectory and Initiatives
Historical Growth: DiaMedica's historical growth is characterized by progress in clinical development rather than revenue generation.
Future Projections: Future growth is entirely dependent on the success of DM199. Analyst projections would be based on probabilities of success and potential market penetration.
Recent Initiatives: Recent initiatives would include enrollment updates for ongoing clinical trials and announcements of new data.
Summary
DiaMedica Therapeutics is a high-risk, high-reward clinical-stage biotech company focused on developing DM199 for stroke and CKD. The company's success hinges on the outcome of its clinical trials, and it currently relies heavily on funding and strategic partnership for survival. Positive clinical results could lead to significant growth, while failure could jeopardize the company's future. DiaMedica needs to secure funding and make it through clinical trials to reach its goal.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The data provided is based on publicly available information and may not be complete or accurate. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DiaMedica Therapeutics Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2008-01-04 | President, CEO & Director Mr. Dietrich John Pauls MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.diamedica.com |
Full time employees 27 | Website https://www.diamedica.com | ||
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.